Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Viking Therapeutics Inc
1VTCurrent price
61.46 EUR
+0.22 EUR (+0.36%)
Last closed
66.73 USD
Company
www.vikingtherapeutics.com
ISIN
US92686J1060
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
7 393 417 216 USD
Yield for 12 month
+385.70 %
1Y
3Y
5Y
10Y
15Y
1VT
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. Address: 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
113.55 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-292 000 USD
Last Year
-291 000 USD
Current Quarter
-75 000 USD
Last Quarter
-74 000 USD
Key Figures 1VT
1 year
3 years
5 years
10 years
EBITDA
–
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-11.57 %
PEG Ratio
-0.03
Return On Equity TTM
-14.8 %
Wall Street Target Price
113.55 USD
Revenue TTM
–
Book Value
8.31 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-0.93 USD
Diluted Eps TTM
-0.93 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 1VT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 1VT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 1VT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-71.6401
Price Book MRQ
8.0278
Financials 1VT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 1VT
For 52 weeks
8.28 USD
99.41 USD
50 Day MA
57.74 USD
Shares Short Prior Month
17 696 767
200 Day MA
51.43 USD
Short Ratio
5.12
Shares Short
17 138 425
Short Percent
20.82 %
BeatStart